New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005
New Zealand's regulatory agency cleared a Phase 1 clinical trial of SRP-1005, a Huntington’s disease therapy candidate from Sarepta.
0 Comments
New Zealand OKs Phase 1 trial of Huntington’s therapy SRP-1005
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed